The Phase II MEDIOLA study of durvalumab plus olaparib in PARPi-naive patients with germline BRCA1/2-mutant platinum-sensitive recurrent ovarian cancer showed a 72% ORR, median duration of response of 10.2 months, and median PFS of 11.1 months [40]. This evidence concerns the gene BRCA1 and ovarian cancer.